Pregnancy: There are no adequate data from the use of liraglutide in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown.
Liraglutide should not be used during pregnancy, and the use of insulin is recommended instead. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Victoza should be discontinued.
Breast-feeding: It is not known whether liraglutide is excreted in human milk. Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk is low. Non-clinical studies have shown a treatment-related reduction of neonatal growth in suckling rat pups (see Pharmacology: Toxicology: Preclinical safety data under Actions). Because of lack of experience, Victoza should not be used during breast-feeding.
Fertility: Apart from a slight decrease in the number of live implants, animal studies did not indicate harmful effects with respect to fertility.